Jorge Matias-Guiu

List of Publications by Year
in descending order

121 papers	2,642 citations	172457 29 h-index	265206 42 g-index
122 all docs	122 docs citations	122 times ranked	3954 citing authors

#	Article	IF	Citations
1	Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Multiple Sclerosis and Related Disorders, 2020, 42, 102185.	2.0	118
2	Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System. Frontiers in Bioengineering and Biotechnology, 2020, 8, 389.	4.1	107
3	Comparative Diagnostic Accuracy of the ACE-III, MIS, MMSE, MoCA, and RUDAS for Screening of Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2017, 43, 237-246.	1.5	80
4	Cognitive dysfunction associated with COVID-19: A comprehensive neuropsychological study. Journal of Psychiatric Research, 2022, 150, 40-46.	3.1	76
5	<i>ACE2, TMPRSS2</i>, and Furin variants and SARS‐CoV‐2 infection in Madrid, Spain. Journal of Medical Virology, 2021, 93, 863-869.	5.0	72
6	One-year prevalence of migraine in Spain: A nationwide population-based survey. Cephalalgia, 2011, 31, 463-470.	3.9	69
7	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. Alzheimer's Research and Therapy, 2018, 10, 85.	6.2	69
8	Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests. International Psychogeriatrics, 2017, 29, 105-113.	1.0	67
9	Infection Mechanism of SARS-COV-2 and Its Implication on the Nervous System. Frontiers in Immunology, 2020, 11, 621735.	4.8	59
10	Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. BMC Neurology, 2015, 15, 243.	1.8	58
11	Spectrum of Headaches Associated With SARS‐CoV‐2 Infection: Study of Healthcare Professionals. Headache, 2020, 60, 1697-1704.	3.9	57
12	CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: Protection by resveratrol but not riluzole. Brain Research, 2011, 1423, 77-86.	2.2	50
13	Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2050-2060.	6.4	48
14	Amyotrophic lateral sclerosis modifies progenitor neural proliferation in adult classic neurogenic brain niches. BMC Neurology, 2017, 17, 173.	1.8	46
15	Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. Frontiers in Neurology, 2016, 7, 53.	2.4	44
16	Clinical course of primary progressive aphasia: clinical and FDG-PET patterns. Journal of Neurology, 2015, 262, 570-577.	3.6	41
17	Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 78, 537-541.	2.6	41
18	Stroke etiology determines effectiveness of retrievable stents: Table 1. Journal of NeuroInterventional Surgery, 2014, 6, e11-e11.	3.3	40

#	Article	IF	Citations
19	Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. Frontiers in Neurology, 2017, 8, 643.	2.4	40
20	Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. Brain and Behavior, 2020, 10, e01498.	2.2	40
21	Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. Journal of Neurology, 2015, 262, 1463-1472.	3.6	39
22	Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study. Journal of Alzheimer's Disease, 2017, 57, 1251-1264.	2.6	38
23	The Adult Macaque Spinal Cord Central Canal Zone Contains Proliferative Cells And Closely Resembles The Human. Journal of Comparative Neurology, 2014, 522, 1800-1817.	1.6	36
24	Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 916-927.	6.4	35
25	Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. Dementia and Geriatric Cognitive Disorders, 2016, 41, 243-250.	1.5	35
26	Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2018, 33, 141-150.	2.7	33
27	Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal. Journal of Medical Virology, 2021, 93, 546-549.	5.0	32
28	Evaluation of the New Consensus Criteria for the Diagnosis of Primary Progressive Aphasia Using Fluorodeoxyglucose Positron Emission Tomography. Dementia and Geriatric Cognitive Disorders, 2014, 38, 147-152.	1.5	31
29	Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 733-742.	2.6	31
30	Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry. Frontiers in Neurology, 2018, 9, 920.	2.4	31
31	Machine learning in the clinical and language characterisation of primary progressive aphasia variants. Cortex, 2019, 119, 312-323.	2.4	31
32	Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study. Scientific World Journal, The, 2015, 2015, 1-8.	2.1	28
33	Is the brain a reservoir organ for SARS‐CoV2?. Journal of Medical Virology, 2020, 92, 2354-2355.	5.0	28
34	Comparison between FCSRT and LASSI-L to Detect Early Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 103-111.	2.6	27
35	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. Frontiers in Immunology, 2020, 11, 2163.	4.8	27
36	An Online Observational Study of Patients With Olfactory and Gustory Alterations Secondary to SARS-CoV-2 Infection. Frontiers in Public Health, 2020, 8, 243.	2.7	27

#	Article	IF	Citations
37	Vitamina D y remielinización en la esclerosis múltiple. Neurología, 2018, 33, 177-186.	0.7	26
38	Inhibition impairment in frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease: clinical assessment and metabolic correlates. Brain Imaging and Behavior, 2019, 13, 651-659.	2.1	26
39	Persistent olfactory dysfunction after COVID‐19 is associated with reduced perfusion in the frontal lobe. Acta Neurologica Scandinavica, 2022, 146, 194-198.	2.1	26
40	Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. Frontiers in Neurology, 2016, 7, 195.	2.4	25
41	The Hayling Test: Development and Normalization of the Spanish Version. Archives of Clinical Neuropsychology, 2016, 31, 411-419.	0.5	25
42	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 2020, 44, 102297.	2.0	25
43	The Neuroprotection Exerted by Memantine, Minocycline and Lithium, against Neurotoxicity of CSF from Patients with Amyotrophic Lateral Sclerosis, Is Antagonized by Riluzole. Neurodegenerative Diseases, 2014, 13, 171-179.	1.4	24
44	Neural Basis of Cognitive Assessment in Alzheimer Disease, Amnestic Mild Cognitive Impairment, and Subjective Memory Complaints. American Journal of Geriatric Psychiatry, 2017, 25, 730-740.	1.2	24
45	Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole‐exome next generation sequencing. Brain and Behavior, 2019, 9, e01272.	2.2	23
46	Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. Frontiers in Aging Neuroscience, 2018, 10, 230.	3.4	22
47	Paroxysmal head pain with backward radiation: will epicrania fugax go in the opposite direction?. Journal of Headache and Pain, 2010, 11, 75-78.	6.0	21
48	Structural MRI correlates of PASAT performance in multiple sclerosis. BMC Neurology, 2018, 18, 214.	1.8	20
49	Alexander Disease Mutations Produce Cells with Coexpression of Glial Fibrillary Acidic Protein and NG2 in Neurosphere Cultures and Inhibit Differentiation into Mature Oligodendrocytes. Frontiers in Neurology, 2017, 8, 255.	2.4	19
50	"Brain Fog" by COVID-19 or Alzheimer's Disease? A Case Report. Frontiers in Psychology, 2021, 12, 724022.	2.1	19
51	Validation of a Spanish Version of the Lille Apathy Rating Scale for Parkinson's Disease. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	18
52	Reading difficulties in primary progressive aphasia in a regular language-speaking cohort of patients. Neuropsychologia, 2017, 101, 132-140.	1.6	18
53	Conversion between Addenbrooke's Cognitive Examination III and Mini-Mental State Examination. International Psychogeriatrics, 2018, 30, 1227-1233.	1.0	17
54	Biohybrids of scaffolding hyaluronic acid biomaterials plus adipose stem cells home local neural stem and endothelial cells: Implications for reconstruction of brain lesions after stroke. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2019, 107, 1598-1606.	3.4	17

#	ARTICLE	IF	CITATIONS
55	Personalized Repetitive Transcranial Magnetic Stimulation for Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 84, 151-167.	2.6	17
56	A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice. International Journal of Molecular Sciences, 2021, 22, 9553.	4.1	17
57	Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 31.	3.0	17
58	Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 629183.	2.4	17
59	Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology. Prion, 2017, 11, 205-213.	1.8	16
60	Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease. Frontiers in Neuroscience, 2019, 13, 302.	2.8	16
61	Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months. Multiple Sclerosis and Related Disorders, 2020, 39, 101926.	2.0	16
62	SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases. Movement Disorders, 2020, 35, 1104-1105.	3.9	16
63	Diagnosis of Alzheimer's disease and behavioural variant frontotemporal dementia with machine learning-aided neuropsychological assessment using feature engineering and genetic algorithms. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	16
64	Validation of the Lille's Apathy Rating Scale in Very Mild to Moderate Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 517-527.	1.2	15
65	Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's Disease: Clinical and FDG-PET Correlation. Journal of Alzheimer's Disease, 2019, 71, 1263-1269.	2.6	15
66	Subventricular zone in motor neuron disease with frontotemporal dementia. Neuroscience Letters, 2011, 499, 9-13.	2.1	14
67	Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. Neurourology and Urodynamics, 2020, 39, 762-770.	1.5	13
68	Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders. Biomedicines, 2022, 10, 1105.	3.2	13
69	Reading prosody in the non-fluent and logopenic variants of primary progressive aphasia. Cortex, 2020, 132, 63-78.	2.4	12
70	Validation of the Neuronorma battery for neuropsychological assessment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102070.	2.0	12
71	GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer's disease and frontotemporal dementia using genetic algorithms. Medical and Biological Engineering and Computing, 2022, 60, 2737-2756.	2.8	12
72	Familial multiple sclerosis and association with other autoimmune diseases. Brain and Behavior, 2018, 8, e00899.	2.2	11

#	Article	IF	Citations
73	Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 638.	2.4	11
74	Long-term directional deep brain stimulation: Monopolar review vs. local field potential guided programming. Brain Stimulation, 2022, 15, 727-736.	1.6	11
75	Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. Journal of Alzheimer's Disease, 2019, 72, 773-782.	2.6	10
76	Design and Verbal Fluency in Alzheimer's Disease and Frontotemporal Dementia: Clinical and Metabolic Correlates. Journal of the International Neuropsychological Society, 2022, 28, 947-962.	1.8	10
77	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. Patient, 2012, 5, 147-162.	2.7	9
78	Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	9
79	Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population. European Neurology, 2016, 76, 202-209.	1.4	9
80	What is the meaning of PASAT rejection in multiple sclerosis?. Acta Neurologica Scandinavica, 2019, 139, 559-562.	2.1	9
81	Identification of the main components of spontaneous speech in primary progressive aphasia and their neural underpinnings using multimodal MRI and FDG-PET imaging. Cortex, 2022, 146, 141-160.	2.4	9
82	FDG-PET/CT or MRI for the Diagnosis of Primary Progressive Aphasia?. American Journal of Neuroradiology, 2017, 38, E63-E63.	2.4	8
83	Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 71-76.	2.0	8
84	Evaluation of the Safety and Efficacy of the Therapeutic Potential of Adipose-Derived Stem Cells Injected in the Cerebral Ischemic Penumbra. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2453-2465.	1.6	8
85	Application of Machine Learning to Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. Brain Sciences, 2021, 11, 1262.	2.3	8
86	Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis. Annals of Neurology, 2016, 80, 166-166.	5.3	7
87	Novedades en esclerosis múltiple: la remielinización como objetivo terapéutico. Medicina Clínica, 2017, 148, 377-380.	0.6	7
88	Amyloid PET in pseudotumoral multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 15, 15-17.	2.0	7
89	Biocompatibility of ferulic/succinic acid-grafted chitosan hydrogels for implantation after brain injury: A preliminary study. Materials Science and Engineering C, 2021, 121, 111806.	7.3	7
90	Neuropsychological Predictors of Fatigue in Post-COVID Syndrome. Journal of Clinical Medicine, 2022, 11, 3886.	2.4	7

#	Article	IF	Citations
91	Spanish Version of the Mini-Linguistic State Examination for the Diagnosis of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 83, 771-778.	2.6	6
92	Intranasal Administration of Undifferentiated Oligodendrocyte Lineage Cells as a Potential Approach to Deliver Oligodendrocyte Precursor Cells into Brain. International Journal of Molecular Sciences, 2021, 22, 10738.	4.1	6
93	Examining Association of Personality Characteristics and Neuropsychiatric Symptoms in Post-COVID Syndrome. Brain Sciences, 2022, 12, 265.	2.3	6
94	The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination. Life, 2022, 12, 474.	2.4	6
95	Factors Associated with the Differences in Migraine Prevalence Rates between Spanish Regions. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	5
96	News in multiple sclerosis: Remyelination as a therapeutic target. Medicina ClÃnica (English Edition), 2017, 148, 377-380.	0.2	5
97	Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimerâ€™s Disease and Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 711-722.	0.5	5
98	Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task. Frontiers in Neurology, 2020, 11, 309.	2.4	5
99	O1â€‘10â€‘05: Pharmacodynamics of the Oral Bace Inhibitor JNJâ€‘54861911 in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P199.	0.8	4
100	Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis. CNS Neuroscience and Therapeutics, 2020, 26, 1178-1184.	3.9	4
101	Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVIDâ€‘19 Pandemic?. Headache, 2020, 60, 1448-1449.	3.9	4
102	Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 5192.	4.1	4
103	Genetic Algorithms for Optimized Diagnosis of Alzheimerâ€™s Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging. Frontiers in Aging Neuroscience, 2021, 13, 708932.	3.4	4
104	Validation of two new scales for the assessment of fatigue in Multiple Sclerosis: F-2-MS and FACIT-F. Multiple Sclerosis and Related Disorders, 2022, 63, 103826.	2.0	4
105	Primary progressive aphasia with occipital impairment. Journal of the Neurological Sciences, 2014, 347, 387-388.	0.6	3
106	Teaching Neuro <i>Images</i> : Adult-onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome). Neurology, 2017, 88, e113-e114.	1.1	3
107	Clinical or neuroimaging profiles in the assessment of genetic variants associated with neurodegenerative diseases. CNS Neuroscience and Therapeutics, 2019, 25, 419-421.	3.9	3
108	Editorial: The Use of Biomaterials With Stem and Precursor Cells in Diseases of the Central Nervous System; A Step to Clinical Trials. Frontiers in Neurology, 2021, 12, 654890.	2.4	3

#	Article	IF	Citations
109	Whole-Exome Sequencing and C9orf72 Analysis in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 80, 985-990.	2.6	3
110	ITH33/IQM9.21 provides neuroprotection in a novel ALS model based on TDP-43 and Na + /Ca 2+ overload induced by VTD. Neuroscience Letters, 2016, 633, 28-32.	2.1	2
111	Amyloid <scp>Positron Emission Tomography</scp> in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damage. Annals of Neurology, 2020, 87, 988-988.	5.3	2
112	The Five-Point Test: Normative data for middle-aged and elderly Spaniards. Applied Neuropsychology Adult, 2022, 29, 1323-1331.	1.2	2
113	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Multiple Sclerosis and Related Disorders, 2022, 63, 103805.	2.0	2
114	Differences in age of diagnosis in familial multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 34, 91.	2.0	1
115	Non-Convulsive Status Epilepticus in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 77, 985-991.	2.6	1
116	Underpinnings of verbal fluency in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103056.	2.0	1
117	Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach. Frontiers in Neurology, 2022, 13, 838227.	2.4	1
118	Repetitive transcranial magnetic stimulation in a case of atypical parkinsonism. Brain Stimulation, 2019, 12, 1343-1344.	1.6	0
119	Validation of the Spanish version of the Mini–Linguistic State Examination for the diagnosis of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e042817.	0.8	0
120	Metabolic correlates of neuropsychological assessment in behavioral variant frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e044097.	0.8	0
121	Personalized repetitive transcranial magnetic stimulation for non–fluent and semantic variants of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e047658.	0.8	0